Delivery Order SPE2DB20D9331-SPE2DB24FL1C9
Award Date
5/16/24
Potential Completion Date
6/7/24
Potential Value
$7.7K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The $9,671.25 firm fixed-price delivery order is for the pharmaceutical product XOLAIR 150 MG/ML SYRINGEML, with a completion date of June 4, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue delivery...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a firm fixed-price delivery order (SPE2DB24FL0H6) under the Defense Logistics Agency's (DLA) SPE2DB program. The $9,284.40 award is for the supply of XOLAIR 75 MG/0.5 ML SYRINGE 0.5ML, a pharmaceutical product, to fulfill the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group is an established federal contractor that provides a comprehensive range of pharmaceutical...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order valued at $7,737.00 for the supply of XOLAIR 150 MG/ML SYRINGEML to the Defense Logistics Agency (DLA), which is the primary logistics and supply agency for the U.S. Department of Defense. The contract has an ultimate completion date of March 4, 2025 and is a firm fixed-price delivery order, with no set-aside designation. DMS Pharmaceutical Group Inc. holds...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $10,647.84 to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of XOLAIR 150 MG/ML syringes. This order is part of a larger $499,999,999 indefinite delivery contract (IDC) that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program, which allows the DLA to issue delivery orders for a comprehensive range of pharmaceutical items to support the recurring...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of XOLAIR 150 MG/ML syringes. The total ceiling value of the order is $77,370.00, with an ultimate completion date of September 23, 2024. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA under the SPE2DB program, which covers a...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of XOLAIR 150 MG/ML SYRINGEML pharmaceutical products to the Defense Logistics Agency (DLA) Medical Supply Chain. The firm fixed-price delivery order, valued at $3,094.80, has an ultimate completion date of October 22, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs...
This federal contract award is a delivery order valued at $9,284.40 issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The award is for the supply of XOLAIR 150 MG/ML SYRINGEML, a specialized pharmaceutical product. The contract is a firm fixed-price delivery order with a period of performance through March 13, 2025. DMS Pharmaceutical Group Inc. holds a larger indefinite delivery contract (IDC) with the DLA...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a firm fixed-price delivery order valued at $7,737.00 for the supply of Xolair 150 mg/ml syringes. The award was made by the Defense Logistics Agency (DLA) under the Medical Supply Chain program, which facilitates the distribution of pharmaceutical products and medical supplies to Department of Defense (DoD) healthcare facilities worldwide. The contract has no set-aside designation and is part of a...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a $1,547.40 firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The contract is for the supply of XOLAIR 150 MG/ML SYRINGE, a specialized pharmaceutical product, with an ultimate completion date of August 12, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The $13,539.75 firm fixed-price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, with a period of performance through September 17, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which...